Avicenna.AI SAS secured a further $7.5 million in series A funding, bringing the total aggregated investment in the company so far to $10.4 million. The round was backed by the two existing Paris-based investors: Cemag Invest SAS and Innovacom Gestion SAS. “Thanks to this funding, we are now able to ramp deployment of our software platform around the world, as well as diversify our offering into new areas of medicine,” Cyril Di Grandi, CEO and co-founder of Avicenna.AI SAS, told BioWorld.
Bionicm Inc. completed a funding round on Feb. 13 to speed up development of its powered prosthetic leg products. The round, valued at “tens of millions of yuan,” was led by Nventure Capital, a wholly owned subsidiary of Nec Capital Solutions Ltd.
Medicinal cannabis company Zelira Therapeutics Ltd. secured $8.6 million in cornerstone funding from U.S.-based Cantheon Capital LLC that will progress Zelira’s Hope1 cannabinoid medicine to formal phase II/III clinical trials for behaviors associated with autism spectrum disorder.
Maxion Therapeutics Ltd. has raised $16 million in a series A to take forward a new method for drugging G-protein coupled receptors (GPCRs) and ion channels with antibodies. The technology brings together naturally occurring knottin peptides that are derived from sources such as snake venom and which can engage GPCRs and ion channels, with antibodies that deliver them to these notoriously difficult, shape-shifting targets.
RSS
